1-7 of 7
Elizabeth A. Punnoose, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Arnon P Kater, MD PhD, Jenny Qun Wu, MS, Julie Dubois, Christopher R Bolen, PhD, Zoe J Assaf, PhD, Peter Hillmen, MD PhD, Barbara F. Eichhorst, MD, Eric F Eldering, PhD, Thomas J. Kipps, MD PhD, Anton W Langerak, PhD, Clemens Mellink, PhD, Anne-Marie Van Der Kevie-Kersemaekers, PhD, Carolyn Owen, MD, Brenda J Chyla, PhD, Elizabeth A Punnoose, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Yanwen Jiang, PhD, John F. Seymour, MBBS, PhD FRACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 356.
https://doi.org/10.1182/blood-2019-123678
Published: 2019
Journal Articles

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Philippe Moreau, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Michael E O'Dwyer, MD, Mamta Garg, MD FRCP, FRCPath, Elizabeth A Punnoose, PhD, Muhammad Jalaluddin, PhD, Jia Jia, PhD MBA, Xiaoqing Yang, PhD, Yan Sun, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Jeremy A. Ross, PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 142.
https://doi.org/10.1182/blood-2019-126094
Published: 2019
Journal Articles

Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Francesca Gay, MD, Gábor Mikala, MD PhD, Elizabeth A Punnoose, PhD, Wan-Jen Hong, MD, Anjla Sood, MD, Muhammad Jalaluddin, PhD, Jeremy A. Ross, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1888.
https://doi.org/10.1182/blood-2019-126015
Published: 2019
Journal Articles

A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax

Jenny Wu, Jeremy Ross, Franklin V. Peale, Jr., John D Shaughnessy, Jr., PhD, Ryan K Van Laar, PhD, Gareth J Morgan, MD PhD, Jeffrey M Venstrom, Elizabeth A. Punnoose, PhD
Journal: Blood
Blood (2016) 128 (22): 5613.
https://doi.org/10.1182/blood.V128.22.5613.5613
Published: 2016
Journal Articles

Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data

Pier Luigi Zinzani, MD PhD, Max S Topp, MD, Sam LS Yuen, MBBS, FRCPA, FRACP, Chiara Rusconi, MD, Isabelle Fleury, MD MSc, FRCPC, Barbara Pro, MD, Giuseppe Gritti, MD, Michael Crump, MD, Wanling Hsu, MS, Elizabeth A. Punnoose, PhD, James Hilger, PhD, Mehrdad Mobasher, MD, Wolfgang Hiddermann, MD
Journal: Blood
Blood (2016) 128 (22): 617.
https://doi.org/10.1182/blood.V128.22.617.617
Published: 2016
Journal Articles

Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, MD, Guillaume Cartron, MD PhD, Michael Hallek, Barbara F. Eichhorst, MD, Mark Kozloff, MD, Thomas A. Giever, Gerard Lozanski, MD, Elizabeth A. Punnoose, PhD, Jue Wang, James Hilger, PhD, Mehrdad Mobasher, MD, Gilles Salles, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4393.
https://doi.org/10.1182/blood.V128.22.4393.4393
Published: 2016
Journal Articles

Mutation Load and a Functional T Effector Signature May Distinguish Immunologically Distinct and Clinically Relevant Lymphoma Subsets

Chris Bolen, PhD, Ronald McCord, PhD, Garrett Frampton, PhD, Richard Bourgon, PhD, Elizabeth A. Punnoose, PhD, Edith Szafer-Glusman, PhD, Pierre Sujobert, MD PhD, Luc Xerri, MD PhD, Sarah Huet, PharmD, PhD, Gilles Salles, MD PhD, Jeffrey M Venstrom
Journal: Blood
Blood (2016) 128 (22): 913.
https://doi.org/10.1182/blood.V128.22.913.913
Published: 2016